Meeting
2020 Gastrointestinal Cancers Symposium
Potency of CD8+ T-cell mediated antitumor immunity from intratumoral immunotherapy with STING agonist, ADU-S100, in an esophageal adenocarcinoma model.
Authors
Laila Babar
The Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA
Laila Babar , Ali Hussainy Zaidi , Ronan Joseph Kelly , Ashten N. Omstead , Ping Zheng , Juliann E. Kosovec , Shahin Ayazi , Gene Grant Finley , Blair Anderson Jobe , Ajay Goel , Anastasia Gorbunova , Madison Salvitti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 408)
Abstract #
408
Poster Bd #
F19
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Efficacy of PD-1 inhibitors in the treatment of advanced gastrointestinal tumors and the effect on T-lymphocyte subsets and IL-6 levels in patients.
First Author: XinCheng He
Poster
2022 ASCO Genitourinary Cancers Symposium
Immune characterization of urothelial bladder carcinoma integrating transurethral resection of bladder tumor (TURBT) samples and serum: A feasibility study.
First Author: Carmen Alvarez-Dominguez
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of immunotherapy in combination with epigenetic therapy in an esophageal adenocarcinoma model.
First Author: Ashten Omstead
Poster
2018 ASCO Annual Meeting
Role of melanoma cell-intrinsic RIG-I and STING signaling for checkpoint inhibitor‑mediated anticancer immunity.
First Author: Simon Heidegger